CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
August 15, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Tamika Sheppard
| Re: | CytomX Therapeutics, Inc. |
Registration Statement on Form S-3 (Registration No. 333-281433)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 19, 2024, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
| Very truly yours, | ||
| CytomX Therapeutics, Inc. | ||
| By: | /s/ Lloyd A. Rowland | |
| Lloyd A. Rowland | ||
| Senior Vice President and General Counsel | ||
| CC: | Sean A. McCarthy, CytomX Therapeutics, Inc. |
Chris Ogden, CytomX Therapeutics, Inc.
Mark V. Roeder, Latham & Watkins LLP
[Signature Page to CytomX Therapeutics, Inc. Acceleration Letter]